Evidence map›Paper›PMID 32182949›Full record

ArticleCancers2020

Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?

Aurore Goineau, Loïc Campion, Jean-Marie Commer, Brigitte Vié, Agnès Ghesquière, Guillaume Béra, Didier Jaffres, Nicolas Magné, Xavier Artignan, Jérôme Chamois and 8 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02876237 (Patient Over 75 Years With Prostate Cancer), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02876237 nacompletednot on this map

Patient Over 75 Years With Prostate Cancer: Geriatric Determinants of General Repercussion of Radiotherapy With Curative Intent

TypeinterventionalSponsorInstitut Cancerologie de l'OuestRan2015 to 2017Enrolled230ConditionsProstate CancerArmsgeriatric assessment and quality of life, Radiotherapy
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 1 country.

Aurore GoineauDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, 49000 Angers, France.
Loïc CampionDepartment of Statistics, Institut de Cancérologie de l'Ouest, CRCINA, University of Nantes, INSERM UMR1232, CNRS-ERL6001, 44800 Saint Herblain, France.ORCID 0000-0003-4903-0908
Jean-Marie CommerDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, 49000 Angers, France.
Brigitte ViéDepartment of Radiation Oncology, Clinique Armoricaine de Radiologie, 22000 St Brieuc, France.
Agnès GhesquièreDepartment of Radiation Oncology, Clinique Armoricaine de Radiologie, 22000 St Brieuc, France.
Guillaume BéraDepartment of Radiation Oncology, Centre Hospitalier de Bretagne Sud, 56100 Lorient, France.
Didier JaffresDepartment of Radiation Oncology, Centre Hospitalier de Bretagne Sud, 56100 Lorient, France.
Nicolas MagnéDepartment of Radiation Oncology, Institut de Cancérologie de Loire, 42270 St Priest en Jarez, France.
Xavier ArtignanDepartment of Radiation Oncology, CHP St Grégoire, 35760 St Grégoire, France.
Jérôme ChamoisDepartment of Radiation Oncology, CHP St Grégoire, 35760 St Grégoire, France.
Philippe BergerotDepartment of Radiation Oncology, Clinique Mutualiste de l'Estuaire, 44600 St Nazaire, France.
Gilles CréhangeDepartment of Radiation Oncology, Centre Georges François Leclerc, 21000 Dijon, France.
Elisabeth Deniaud-AlexandreDepartment of Radiation Oncology, Centre Hospitalier Départemental de Vendée, 85000 La Roche sur Yon, France.
Xavier ButhaudDepartment of Radiation Oncology, Centre Catherine de Sienne, 44000 Nantes, France.
Yazid BelkacémiDepartment of Radiation Oncology, CHU Henri Mondor, 94000 Créteil, France.
Mélanie DoréDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.
Laure De DeckerDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.
Stéphane SupiotDepartment of Radiation Oncology, Institut de Cancérologie de l'Ouest, 44800 Saint Herblain, France.ORCID 0000-0003-2094-1708
Institut de Cancérologie de l'Ouest · FRCentre Hospitalier de Bretagne Sud · FRCentre Hospitalier privé Saint Grégoire · FRCentre Georges François Leclerc · FRCentre Hospitalier Universitaire Henri-Mondor · FRCentre National de la Recherche Scientifique · FRClinique Mutualiste de l'Estuaire · FRInstitute Cancer De La Loire Lucien Neuwirth · FRInstitut Sainte Catherine · FRRoche (France) · FR

Funding

Unité de Coodination en Onco-Gériatrie des Pays de Loire 0
6 · The paper itself

Abstract

Curative radiotherapy for prostate cancer is common in the elderly. However, concerns about potential toxicity have inhibited access to radiotherapy for this population, for whom preserving quality of life (QoL) is crucial. The primary endpoint was to identify predictors of impaired QoL in men aged 75 years or older treated with curative intent radiotherapy with or without androgen deprivation therapy (ADT) for localized prostate cancer. We prospectively performed comprehensive geriatric assessment (CGA) and administered QoL questionnaires to 208 elderly (>75 years) patients prior to, plus two and six months after, radiotherapy (NCT02876237). The median age of the patients was 77 years (range 75-89). At the start of the study, comorbidities were highlighted in 65% of patients: 23% were depressed, 23% had cognitive impairment, and 16% had reduced independence. At six months, 9% of patients had a consistently decreased QoL (>20 points), and a further 16% had a more moderate reduction (10 to 20 points) in QoL. None of the parameters studied (tumor characteristic, treatment, or oncogeriatric parameters) were predictive of a reduced QoL following radiotherapy. Though co-existing geriatric impairment was common, QoL was maintained for 75% of patients six months after radiotherapy. CGA was poorly predictive of tolerance of prostatic radiotherapy. Geriatric assessments dedicated to quality of life following radiotherapy need to be developed.

Indexed as

comprehensive geriatric assessmentgeriatric rating scalesprostate cancerquality of liferadiotherapytoxicity

Identifiers

PMID32182949
PMCPMC7139355
OpenAlexW3009100116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.